Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Akari Therapeutics ADR (AKTX)

Akari Therapeutics ADR (AKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Akari Therapeutics Announces Appointment of Samir R. Patel, M.D. as CEO and Abizer Gaslightwala to Board of Directors

Akari Therapeutics announces Samir R. Patel as CEO and Abizer Gaslightwala's appointment to the Board of Directors.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Samir R. Patel,...

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Key Leadership Appointments

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics appoints Dr. Torsten Hombeck as CFO, strengthening leadership with expertise in biotechnology and finance.Quiver AI SummaryAkari Therapeutics, Plc announced the appointment of Dr. Torsten...

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Regains Full Nasdaq Compliance

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Completes Merger with Peak Bio and Secures $3.2 Million in PIPE Financing

Akari Therapeutics secures $3.2 million in PIPE financing and a $50 million equity line of credit following its merger with Peak Bio.Quiver AI SummaryAkari Therapeutics, Plc has completed a merger with...

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

AKTX : 0.9500 (-2.06%)
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

AKTX : 0.9500 (-2.06%)
PKBO : 0.0225 (-67.86%)
Akari Therapeutics Narrows Pipeline Focus

NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

AKTX : 0.9500 (-2.06%)

Barchart Exclusives

Why This Dividend Stock Just Scored a Rare Upgrade
Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar